## Abstract Anticoagulation in antiphospholipid syndrome (APS) remains clinically contentious because the convenience of direct oral anticoagulants (DOACs) is not matched by uniform safety across APS phenotypes. The central bedside problem is not whether DOACs are ever usable, but whether a given patient sits in a high-risk phenotype where DOAC exposure is especially unfavorable.
Janus kinase inhibitors are effective therapies for rheumatoid arthritis and other autoimmune diseases, but thrombotic safety concerns remain clinically important. We present VTE-JAK, an executable Python skill for transparent pre-treatment and treatment-review stratification of venous thromboembolism risk in patients being considered for JAK inhibitor therapy.
Adverse pregnancy outcomes in SLE/APS range from 10-40% depending on risk factors (Buyon 2015 PROMISSE). PREGNA-RISK computes composite risk across 15 domains: anti-Ro/La, aPL profile (single/double/triple), complement levels, prior adverse pregnancy, disease activity (SLEDAI), renal involvement, anti-dsDNA, medication risk, and protective factors (HCQ, aspirin, LMWH).
Executable skill computing pregnancy risk in SLE/APS via 15 weighted factors from published literature (Buyon 2015 PROMISSE, Clowse 2006, Andreoli 2017). Monte Carlo (1000 iterations) produces risk distributions.
We describe a weighted composite score for pregnancy risk stratification in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). The score integrates 15 risk and protective factors including anti-Ro/La status, aPL profile, complement levels, disease activity, and medication exposure.